January 31, 2015 6:45 PM ET


Company Overview of Neurimmune Holding AG

Company Overview

Neurimmune Holding AG, a biotechnology company, engages in the development and commercialization of human antibody therapeutics for the treatment and prevention of common human diseases. The company focuses on protein aggregation diseases; and neurodegenerative disorders, such as Alzheimer’s disease. Its pipeline comprises programs in neurodegeneration, including Alzheimer's and Parkinson's diseases, tauopathies, and amyotrophic lateral sclerosis or Lou Gehrig's disease. The company develops human monoclonal antibodies as therapeutics based on its Reverse Translational Medicine technology platform. Neurimmune Holding AG was founded in 2006 and is based in Schlieren, Switzerland.

Wagistrasse 13

Schlieren,  8952


Founded in 2006


41 44 755 46 46


41 44 755 46 47

Key Executives for Neurimmune Holding AG

Founder and Chief Scientific Officer
Chief Financial Officer
Chief Operating Officer and General Manager
Compensation as of Fiscal Year 2014.

Neurimmune Holding AG Key Developments

Neurimmune Holding AG Presents at 7th Annual European Life Sciences CEO Forum, Mar-04-2014 through Mar-05-2014

Neurimmune Holding AG Presents at 7th Annual European Life Sciences CEO Forum, Mar-04-2014 through Mar-05-2014. Venue: Hilton Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Switzerland. Presentation Date & Speakers: Mar-04-2014, Michael Salzmann, Chief Operating Officer and General Manager.

ALS Therapy Development Institute and Neurimmune Partner to Advance Treatments for ALS

ALS Therapy Development Institute together with its wholly-owned subsidiary, Anelixis Therapeutics, announced that it has formed a research partnership with Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig's disease. The research partnership will explore a human monoclonal antibody that targets misfolded superoxide dismutase 1 (SOD1). Misfolded SOD1 accumulates in familial and sporadic ALS, suggesting a generalized role as a drug target for ALS treatments. The collaboration will explore the high-affinity human antibodies developed by Neurimmune that selectively target misfolded SOD1. In preclinical studies with transgenic mice, chronic antibody treatment significantly reduced SOD1 pathology and rescued spinal cord motor neurons, resulting in significantly reduced muscle atrophy, better motor functions and increased survival.

Similar Private Companies By Industry

Company Name Region
Osmopharm SA Europe
Celgene International Sarl Europe
mondoBIOTECH AG Europe
Qiagen AG Europe
SMtec Biovision Holding AG Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Neurimmune Holding AG, please visit www.neurimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.